Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Full text

Free full text

Publication Types

Journal Article

Research Support, Non-U.S. Gov't

Clinical Trial

Randomized Controlled Trial

Comparative Study

Review

Observational Study

Controlled Clinical Trial

Multicenter Study

Clinical Trial, Phase II

Case Reports

Research Support, U.S. Gov't, P.H.S.

Meta-Analysis

Systematic Review

Letter

Publication Year

From

Quick links

Individual year

2024

2022

2021

2020

2018

2017

2016

2015

2014

2013

2011

2010

2009

2008

2007

2006

2005

2004

2003

2002

2001

2000

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Antithrombin III""[mesh_terms]

60 Results

Searching titles within these results

Exploring antithrombin: insights into its physiological features, clinical implications and analytical techniques.

Hassan A Hamali, Gasim Dboie, Aymen M Madkhali, Abdullah A Mobarki, Muhammad Saboor

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2024;35(2):43-48

Full Text

Abstract

Prophylaxis with AT III for thromboembolism in nephrotic syndrome: why should it be done?

Marco Zaffanello, Milena Brugnara, Vassilios Fanos, Massimo Franchini

International urology and nephrology 2009;41(3):713-6

Full Text

Abstract

A pharmacologic overview of current and emerging anticoagulants.

Edith A Nutescu, Nancy L Shapiro, Aimee Chevalier, Alpesh N Amin

Cleveland Clinic journal of medicine 2005;72 Suppl 1():S2-6

Free Full Text

Abstract

Effects of tibolone on fibrinogen and antithrombin III: A systematic review and meta-analysis of controlled trials.

Małgorzata Bała, Amirhossein Sahebkar, Sorin Ursoniu, Maria-Corina Serban, Anetta Undas, Dimitri P Mikhailidis, Gregory Y H Lip, Jacek Rysz, Maciej Banach

Pharmacological research 2018;124():64-73

Full Text

Abstract

A novel SERPINC1 frameshift mutation in two antithrombin deficiency families.

Boyang Sun, Xian Zhang, Huiyuan Li, Yani Lin, Li Qin, Renchi Yang, Kun Ru, Long Chen, Lei Zhang, Donglei Zhang

International journal of laboratory hematology 2020;42(2):e48-e51

Full Text

Evolving concepts in the treatment of venous thromboembolism: the role of factor Xa inhibitors.

Edith A Nutescu, Cathy M Helgason

Pharmacotherapy 2004;24(7 Pt 2):82S-87S

Full Text

Abstract

Homozygous antithrombin deficiency type II (99 Leu to Phe mutation) and childhood thromboembolism.

S Kuhle, D A Lane, K Jochmanns, C Male, P Quehenberger, K Lechner, I Pabinger

Thrombosis and haemostasis 2002;86(4):1007-11

Full Text

Abstract

Use of Andexanet Alfa for Factor Xa Inhibitor Reversal in US Verified Trauma Centers: A National Survey.

Abenámar Arrillaga, Dajana Reci, Paul Joseph, Younghee Hahn, Tenzing Japhe, Lauren Rothburd, Catherine Caronia, Charles Fasanya, Patricia Eckardt

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2024;30():10760296241238013

Free Full Text

Abstract

Antithrombin and first complement protein recognize the same active heparin fraction.

Graciela C Calabrese, Eduardo F Recondo, Marta E Fernandez de Recondo

Thrombosis research 2003;105(6):537-41

Full Text

Abstract

New anticoagulant therapy.

Jeffrey I Weitz, Lori-Ann Linkins

Annual review of medicine 2005;56():63-77

Full Text

Abstract

Hemostatic problems and thromboembolic complications in nephrotic children.

A Citak, S Emre, A Sâirin, I Bilge, A Nayir

Pediatric nephrology (Berlin, Germany) 2000;14(2):138-42

Full Text

Abstract

Human beta-tryptase: detection and characterization of the active monomer and prevention of tetramer reconstitution by protease inhibitors.

Yoshihiro Fukuoka, Lawrence B Schwartz

Biochemistry 2004;43(33):10757-64

Full Text

Abstract

Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients.

Demetrios J Kutsogiannis, R T Noel Gibney, Daniel Stollery, Jun Gao

Kidney international 2005;67(6):2361-7

Free Full Text

Abstract

Impact of non-di-(2-ethylhexyl)phthalate cardiopulmonary bypass tubes on inflammatory cytokines and coagulation-fibrinolysis systems during cardiopulmonary bypass.

Yosuke Takahashi, Toshihiko Shibata, Yasuyuki Sasaki, Hiromichi Fujii, Takeshi Ikuta, Yasuyuki Bito, Atsushi Nakahira, Shigefumi Suehiro

Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs 2010;12(4):226-31

Full Text

Abstract

Antithrombin supplementation for prevention of vascular thrombosis after pediatric liver transplantation.

Maria Hukkinen, Michela Wong, Zeynep Demir, Radhia Hadj Salem, Dominique Debray, Sylvain Renolleau, Samira Sissaoui, Florence Lacaille, Muriel Girard, Mehdi Oualha, Stefania Querciagrossa, Monique Fabre, Cecile Lozach, Rozenn Clement, Dominique Lasne, Delphine Borgel, Carmen Capito, Christophe Chardot

Journal of pediatric surgery 2022;57(11):666-675

Full Text

Abstract

Results: 1 – 15 / 60

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Antithrombin III""[mesh_terms]

Exploring antithrombin: insights into its physiological features, clinical implications and analytical techniques.

Prophylaxis with AT III for thromboembolism in nephrotic syndrome: why should it be done?

A pharmacologic overview of current and emerging anticoagulants.

Effects of tibolone on fibrinogen and antithrombin III: A systematic review and meta-analysis of controlled trials.

A novel SERPINC1 frameshift mutation in two antithrombin deficiency families.

Evolving concepts in the treatment of venous thromboembolism: the role of factor Xa inhibitors.

Homozygous antithrombin deficiency type II (99 Leu to Phe mutation) and childhood thromboembolism.

Use of Andexanet Alfa for Factor Xa Inhibitor Reversal in US Verified Trauma Centers: A National Survey.

Antithrombin and first complement protein recognize the same active heparin fraction.

New anticoagulant therapy.

Hemostatic problems and thromboembolic complications in nephrotic children.

Human beta-tryptase: detection and characterization of the active monomer and prevention of tetramer reconstitution by protease inhibitors.

Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients.

Impact of non-di-(2-ethylhexyl)phthalate cardiopulmonary bypass tubes on inflammatory cytokines and coagulation-fibrinolysis systems during cardiopulmonary bypass.

Antithrombin supplementation for prevention of vascular thrombosis after pediatric liver transplantation.

Results for
""Antithrombin III""[mesh_terms]